Cargando…

THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma

Patients newly diagnosed with metastatic pancreatic ductal adenocarcinoma generally have poor survival, with heterogeneous rates of progression. Biomarkers that could predict progression and/or survival would help inform patients and providers as they make care decisions. In a previous retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Gimotty, Phyllis A., Till, Jacob E., Udgata, Shirsa, Takenaka, Naomi, Yee, Stephanie S., LaRiviere, Michael J., O’Hara, Mark H., Reiss, Kim A., O'Dwyer, Peter, Katona, Bryson W., Herman, Daniel, Carpenter, Erica L., Zaret, Kenneth S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555682/
https://www.ncbi.nlm.nih.gov/pubmed/34733417
http://dx.doi.org/10.18632/oncotarget.28099
Descripción
Sumario:Patients newly diagnosed with metastatic pancreatic ductal adenocarcinoma generally have poor survival, with heterogeneous rates of progression. Biomarkers that could predict progression and/or survival would help inform patients and providers as they make care decisions. In a previous retrospective study, we discovered that circulating thrombospondin-2 (THBS2) could, in combination with CA19-9, better distinguish patients with PDAC versus healthy controls. Here we evaluated whether THBS2 levels, previously not known to be prognostic, were associated with outcome in 68 patients at time of diagnosis of metastatic PDAC. Specifically, we interrogated the association of THBS2 level, alone or in combination with CA19-9, with progression by 90 days and/or survival to 180 days. The results indicate that elevated THBS2 levels alone, at the time of a metastatic PDAC diagnosis, can identify patients with a shorter time to death and thus help patients and providers when planning treatment.